TREATMENT OF MAGE-A4 POSITIVE CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 12, 2024
app pub date -
May 20, 2024
filing date -
Dec 1, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Methods are presented for the administration of a TCR-anti-CD3 fusion molecule to treat patients who have a MAGE-A4 positive cancer. The methods comprise administering an TCR-anti-CD3 fusion molecule to a patient intravenously and comprise administration of (a) at least one first dose in the range of from 10-20 μg; (b) at least one second dose in the range of from 40-50 μg; and then (c) at least one third dose in the range of from 90-400 μg, wherein doses are administered every 6-8 days.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully